Business description: Trinity Biotech plc

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Number of employees: 287

Sales by Activity: Trinity Biotech plc

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Clinical Laboratory Goods

- 58.29M 42.29M 39.37M 31.68M

Point-Of-Care Products

- 9.21M 9.09M 17.43M 8.1M

Acquires, Manufactures and Markets a Range of Diagnostic Products

92.96M - - - -

Clinical Laboratory Services

- 7.27M 5.45M 4.75M 4.01M

Geographical breakdown of sales: Trinity Biotech plc

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Americas

116M 76.62M 66.85M 61.61M 51.98M

Rest of World - Ireland

28.23M 25.1M 12.72M 20.46M 15M

Eliminations

-51.58M -26.94M -22.74M -20.52M -23.19M

Executive Committee: Trinity Biotech plc

Manager TitleAgeSince
Chief Executive Officer 45 16/12/2023
Director of Finance/CFO - 22/12/2025
Chief Operating Officer - 31/12/1996
Chief Tech/Sci/R&D Officer 53 30/09/2022
Chief Tech/Sci/R&D Officer 42 31/08/2015

Composition of the Board of Directors: Trinity Biotech plc

Director TitleAgeSince
Chairman 70 30/04/1995
Director/Board Member 67 -
Director/Board Member 45 -
Director/Board Member 69 25/10/2022
Director/Board Member - 28/09/2023
Director/Board Member 46 20/08/2025

Shareholders: Trinity Biotech plc

NameStocks%Valuation
Hunter Associates Investment Management LLC
2.864 %
536,210 2.864 % 376 956 $
Yorkville Advisors Global LP
1.202 %
225,000 1.202 % 158 175 $
Williams & Novak LLC
0.575 %
107,643 0.575 % 75 673 $
Virtu Financial LLC
0.1425 %
26,676 0.1425 % 18 753 $
Moss Adams Wealth Advisors LLC
0.1371 %
25,666 0.1371 % 18 043 $
NameStocks%Valuation
MiCo IVD Holdings, LLC
53.53 %
44,759,380 53.53 % 8 M $
11.63 %
9,724,160 11.63 % 2 M $
Novus Diagnostics Ltd.
1.34 %
1,119,988 1.34 % 196 838 $
0.2392 %
200,000 0.2392 % 35 150 $
0 %
0 0 % - $

Company details: Trinity Biotech plc

Trinity Biotech Plc

IDA Business Park

10, Bray

+353 1 276 9800

http://www.trinitybiotech.com
address Trinity Biotech plc(TRIB)

Diagnostic & Testing Substances

Change 5-day change 1-year change 3-year change Capi.($)
-3.70%-2.62%-3.03%-87.62% 13.67M
+0.55%+4.78%+168.50%+278.98% 17.36B
-1.74%-7.00%-44.69%-25.52% 9.37B
+0.19%+3.51%+30.42%+24.46% 6.79B
-0.17%+8.98% - - 5.09B
-0.39%-2.02%-33.64%-24.80% 5.07B
-2.92%-6.89%-29.54%-31.71% 4.18B
-1.36%-13.84%+63.84%+50.85% 3.81B
-0.72%-7.09%+172.59%-48.36% 3.69B
+0.64%+0.51%-18.74%-41.37% 2.62B
Average -0.96%-2.85%+33.97%+10.55% 5.8B
Weighted average by Cap. -0.46%-2.61%+61.41%+83.47%
  1. Stock Market
  2. Stocks
  3. TRIB Stock
  4. Company Trinity Biotech plc
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!